The number of physician-scientists working in lung cancer has not kept pace with the overall growth of the medical research community or with the growth in our basic knowledge base, resulting in an increasing number of unrealized basic and translational research opportunities. Yale is uniquely suited to helping rebuild this base with our strong commitment to translational research. The Career Enhancement Program (CEP) of the Yale SPORE in Lung Cancer (YSILC) has been designed to contribute substantively to ongoing efforts and new initiatives attempting to address this problem. The goal of the CEP is to educate a new generation of investigators committed to translational research in lung cancer. The CEP has substantial institutional commitment, both in terms of funding and infrastructure. For example, our translational research office at Yale (also led by Dr. Herbst, YSILC PI) has been committed to providing early seed funding and translational support to young investigators early in their research careers. Potential CEP candidates include promising junior faculty who are interested in establishing their careers in translational lung cancer research and/or established investigators whose previous research has been in other areas and would like to transition into lung cancer focused research. Junior faculty awardees will be paired with mentors who are more established lung cancer investigators with a documented record of successful mentoring. In this way, the YSILC will stimulate the development of the next generation of physician scientists, addressing the most challenging issues in lung cancer research.
PROGRAM NARRATIVE The Yale SPORE in Lung Cancer?s Career Enhancement Program is a key program to foster the development of the next generation of physician scientists focused on conducting research in the area of human thoracic malignancies to advance discoveries in the prevention, diagnosis, and treatment of lung cancer.
|Wilson, Frederick H; Politi, Katerina (2018) ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discov 8:676-678|
|Wang, Guangchuan; Chow, Ryan D; Ye, Lupeng et al. (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Anastasiadou, Eleni; Jacob, Leni S; Slack, Frank J (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5-18|
|Bisserier, Malik; Wajapeyee, Narendra (2018) Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131:2125-2137|
|Chow, Ryan D; Chen, Sidi (2018) Cancer CRISPR Screens In Vivo. Trends Cancer 4:349-358|
|Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270|
|Goldberg, Sarah B; Narayan, Azeet; Kole, Adam J et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 24:1872-1880|
|Gilles, Maud-Emmanuelle; Slack, Frank J (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22:929-939|
|Nagarajan, Maxwell B; Tentori, Augusto M; Zhang, Wen Cai et al. (2018) Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Anal Chem 90:10279-10285|
Showing the most recent 10 out of 74 publications